Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,801–3,900 of 4,628
Raghu, G., Rochwerg, B. N., Zhang, Y., Cuello‐García, C. A., Azuma, A., Behr, J., Brożek, J., Collard, H. R., Cunningham, W., Homma, S. A., et al. (2017) · Advances in respiratory medicine · doi:10.5603/arm.50373
Self-citationCurrent pharmacotherapy of idiopathic pulmonary fibrosis
Vašáková, M. (2016) · Klinická farmakologie a farmacie · doi:10.36290/far.2016.006
Vicary, G. W. (2016) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2589
[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]
Belisari, A., Bettoni, D., Cortesi, P. A., D’Angiolella, L. S., Mantovani, L. G., Sopo, G. M., & Nonis, M. (2017) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v18i1s.1300
Reply: Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Costabel, U., Stansen, W., & Stowasser, S. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201610-2155le
Self-citationRespiratory Failure in a Patient with Idiopathic Pulmonary Fibrosis
Hadley, R. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-43341-7_30 · Cited by 2
Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers
Anaev, E. K. (2017) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-1-56-64 · Cited by 2
Krankheitsprogression der IPF kann verlangsamt werden
Jäger-Becker, D. (2017) · Pneumo News · doi:10.1007/s15033-017-0709-6
III. New Treatment of Idiopathic Pulmonary Fibrosis
Kashiwada, T., & Azuma, A. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.970
Self-citation“An Ounce of Prevention.. ”: Will This Be the Future for Idiopathic Pulmonary Fibrosis?
Lee, J. S. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1116ed
Neue Ansätze zur Verzögerung der Krankheitsprogression
Ameri, A. A. (2015) · Pneumo News · doi:10.1007/s15033-015-0169-9
Delving Deep into the Proteome of Lung Fibrosis Brings Plasma Cells to the Surface
Gibbons, M., & Scotton, C. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1186ed · Cited by 1
Treatment of Pulmonary Hypertension in Interstitial Lung Disease
King, C. S., & Nathan, S. D. (2017) · Springer eBooks · doi:10.1007/978-3-319-49918-5_4
Tanizawa, K., Collard, H. R., & Ryerson, C. J. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10015916
Self-citationPathology of Vascular Changes in Interstitial Lung Diseases
Nunès, H., Dorfmüller, P., Uzunhan, Y., Valeyre, D., Bernaudin, J., & Kambouchner, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-49918-5_3
Pharmakologische und nicht-pharmakologische Therapie der idiopathischen Lungenfibrose
Schertel, A., Funke-Chambour, M., & Geiser, T. (2017) · Praxis · doi:10.1024/1661-8157/a002770
Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis
Sgalla, G., & Richeldi, L. (2017) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2017.08.005
Self-citationPhysical fitness, fatigue and physical training in sarcoidosis
Strookappe (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170124ews
Seeing Deeply into the Lung in Interstitial Lung Disease
Kaner, R. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201709-1798ed
Exogen-allergische Alveolitis — ein weiterhin aktuelles Thema
Knoop, U., & Knoop, H. (2017) · Pneumo News · doi:10.1007/s15033-017-0760-3
Kombinationstherapie bei IPF erfolgreich
Jäger-Becker, D. (2017) · Pneumo News · doi:10.1007/s15033-017-0802-x
Kuś, J. (2017) · Advances in respiratory medicine · doi:10.5603/arm.50374
Idiopathic Pulmonary Fibrosis: Treatment Strategies
Varela, B. E., & Tabaj, G. C. (2015) · Clinical Anti-Inflammatory & Anti-Allergy Drugs · doi:10.2174/221270380102150520112938
Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis
Strel’tsov, E. A. (2018) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2018-9-1-17-22
Zyryanov, S. K., Butranova, O. I., & Shatalova, O. V. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-6-789-802
Therapeutic Strategies for Interstitial Lung Diseases in Rheumatoid Arthritis
Suda, T. (2018) · Springer eBooks · doi:10.1007/978-981-10-6750-1_9
Schaeffer, M. R. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0364703
Experten-Empfehlungen zur transbronchialen Kryobiopsie
Gesierich, W. (2018) · Pneumo News · doi:10.1007/s15033-018-0882-2
Szturmowicz, M., Kacprzak, A., & Kuś, J. (2018) · Advances in respiratory medicine · doi:10.5603/arm.57075
It takes a village to care for the patient with idiopathic pulmonary fibrosis
Fischer, A. (2018) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.85a.17117
Therapeutic approach and molecular targets for novel treatments
Sgalla, G., Jones, M. G., & Richeldi, L. (2015) · doi:10.2217/fmeb2013.14.74
Self-citationLee, J. S., & Fontenot, A. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00072-7
Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis
Ho, L. A., & Raghu, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-90525-9_16
Self-citation[Hemodynamic effects of disopyramide and procainamide in open-chest animals].
Binetti, G. G., Branzi, A., Malini, P. L., Specchia, S., Magelli, C., Zannoli, R., & Magnani, B. (1978) · PubMed
Pretransplant Considerations in Patients with Pulmonary Fibrosis
Carbone, R. G., Monselise, A., Wille, K. M., Bottino, G., & Puppo, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-91184-7_4
Diffuse Parenchymal Lung Diseases in the Elderly
Walsh, S. M., & O'Regan, A. W. (2018) · Current Geriatrics Reports · doi:10.1007/s13670-018-0249-x
Meachery, G. J., & Corris, P. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-91184-7_2
Who and When to Transplant: What Has Changed?
Seneviratne, I. N. S., & Hopkins, P. M.-A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90933-2_1 · Cited by 2
Lung Transplantation for Interstitial Lung Disease
Malouf, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90933-2_12
Lung Transplantation in Interstitial Lung Disease
Paoletti, L., & Whelan, T. P. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00009-4
Natural History of Idiopathic Pulmonary Fibrosis and Disease Monitoring
Sergew, A., & Brown, K. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00009-3
Self-citationPérez, E. R. F., Amigues, I., & Solomon, J. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54431-3.00008-1
Respiratory Organ Aging and Cancer
Witt, L. J., & Presley, C. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-44870-1_63-1
Connective Tissue Related Interstitial Lung Disease
Gadre, A., & Highland, K. B. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0212-5 · Cited by 1
Taugt bei akut exazerbierter idiopathischer Lungenfibrose der Kortisonstoß noch?
Polke, M., & Kreuter, M. (2018) · Pneumo News · doi:10.1007/s15033-018-0817-y
The Role of Mast Cells in the Pathophysiology of Pulmonary Fibrosis
Shimbori, C., Upagupta, C., Forsythe, P., & Kolb, M. R. J. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_6
Self-citationSildenafil zum Nintedanib hat bei IPF keinen Vorteil
Markart, P., & Günther, A. (2018) · Pneumo News · doi:10.1007/s15033-018-1045-1
Update zur idiopathischen Lungenfibrose
Jäger-Becker, D. (2019) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-019-0189-1
Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis
Buendía-Roldán, I., Mejía, M. E., & Selman, M. (2018) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2018.09.018
Self-citationFibrosis and Immune Dysregulation in Systemic Sclerosis
Argobi, Y., & Smith, G. P. (2018) · Molecular and translational medicine · doi:10.1007/978-3-319-98143-7_2 · Cited by 2
Antifibrotics: Shrinking the Box of Therapeutic Uncertainty
Guler, S. A., & Funke-Chambour, M. (2018) · Respiration · doi:10.1159/000494275
Gastroesophageal Reflux and IPF
Lee, J. S. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_15 · Cited by 1
Bouvry, D. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30049-1 · Cited by 1
3) Pulmonary Fibrosis and Its Management
Azuma, A. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.2183
Self-citationBiomarker discovery and drug testing in Idiopathic Pulmonary Fibrosis
Fernandez, I. E. (2018) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.23287
Exercise in Interstitial Lung Diseases
Vainshelboim, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-05258-4_7
Langfristige Reduktion von Exazerbationen und Lungenfunktionsverlust
Einecke, D. (2019) · Pneumo News · doi:10.1007/s15033-019-1175-0
Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis
Chung, A., English, J., & Volkmann, E. R. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00121-1
Fibrose pulmonaire idiopathique : progrès étiologiques, diagnostiques, et thérapeutiques
Cordier, J.-F. (2014) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)31230-0
Telomere-Related Gene Mutations and Lung Diseases: Pulmonary Fibrosis, Emphysema and Lung Cancer
Sastre, L., Molina‐Molina, M., & Perona, R. (2026) · Barcelona Respiratory Network · doi:10.23866/brnrev:2018-0010 · Cited by 2
Clinical Meaning of Transbronchial Cryobiopsy
Puglisi, S., Ravaglia, C., Arcadu, A., Tomassetti, S., & Poletti, V. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-14891-1_10
Neue Wege in der Therapie der SSc-ILD: Was macht Sinn?
Kreuter, M., & Hoffmann‐Vold, A. (2019) · Der Pneumologe · doi:10.1007/s10405-019-0269-z
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévôt, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.020 · Cited by 1
Self-citationIdentifying “Real” Patients in the Real World
Callahan, S. J. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201907-1458le
Acute Hypoxemic Respiratory Failure: Idiopathic Pulmonary Fibrosis
Farris, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-26664-6_15
An efficacy of ninedanib in patients with idiopathic pulmonary fibrosis (two case reports)
Terpigorev, S. A., Nikishenkov, A. M., & Nikishenkova, S. G. (2019) · PULMONOLOGIYA · doi:10.18093/0869-0189-2019-29-4-486-492
Idiopathic Pulmonary Fibrosis-Treatment and Management
Collins, B. F., & Raghu, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11455-2
Self-citationNeuraxial anesthesia and nintedanib use: a word of caution
Soberón, J. R., Mason, J. B., Dauer, L. C., et al. (2019) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2019-101079
Neue Wege in der Therapie der SSc-ILD: Was macht Sinn?
Kreuter, M., & Hoffmann‐Vold, A. (2019) · Pneumo News · doi:10.1007/s15033-019-1310-y
The Role of the Ovarian Cancer G -Coupled Receptor (OGR1) in Idiopathic Pulmonary FibrosisPreprint
Nagel, D. J., Clough, R., Bell, T. J., Ku, W.-Y., Sime, P. J., & Kottmann, R. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/849117 · Cited by 1
“In 2014, two new medications were approved for the treatment of IPF (Nintedanib and Pirfenidone)[2, 3].”
BackgroundMedizin, S. (2019) · Pneumo News · doi:10.1007/s15033-019-1330-7
The Role of the Innate Immune System in Interstitial Lung Disease
Hogaboam, C. M., Hohmann, M. S., & Espíndola, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11575-2
Idiopathic Nonspecific Interstitial Pneumonia. A Case Series and Literature Review
Ronda, V. E., Safont, B., Landete, M. Á. M., Mestre‐Alagarda, C., & Izquierdo, A. F. (2020) · Open Respiratory Archives · doi:10.1016/j.opresp.2020.02.002
Hope in Patients With Progressive Fibrosis Interstitial Lung Disease (PF-ILD)
Jirru, E., & Zappetti, D. (2020) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000342
Nintedanib bei progressiven fibrosierenden interstitiellen Lungenerkrankungen
Hadjiski, D. (2020) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-020-00782-7
Beyond standard care?—idiopathic pulmonary fibrosis patients’ perception of care coordinators
Hagmeyer, L., & Randerath, W. J. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.40
Morphological and functional studies in a sheep model of pulmonary fibrosis
Dewage, V., & Nimanthi, S. (2020) · Minerva Access (University of Melbourne)
Modern approach to therapy of patients with idiopathic pulmonary fibrosis
Oa, T., Олеговна, В. О., & Евгеньевна, Б. О. (2017) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2017-95-3-281-285
Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?
Sgalla, G., & Richeldi, L. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20200193
Self-citationIdiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?
Spek, C. A., & Duitman, J. (2020) · European Respiratory Journal · doi:10.1183/13993003.00811-2020 · Cited by 2
ERKRANKUNGEN DER ATMUNGSORGANE
Jung, N., Mayet, W.-J., Mertens, P. R., (federführend), J. M., Müller, O.-A., Pfeifer, R., Schellinger, P. D., Weiss, N., & Wendtner, C. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50010-3
Weissferdt, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-36438-0_3
WILSHER, M. L., & Beckert, L. (2020) · Respirology · doi:10.1111/resp.13906
New developments in respiratory medicine: a primary immunodeficiency perspective
Ng, K. L., & Hurst, J. R. (2020) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000690
Use of biologics in the treatment of asthma, COPD, ACOS, and idiopathic pulmonary fibrosis
Chakraborty, A., & Royce, S. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00005-4 · Cited by 1
Seibold, J. R., KOHLBRENNER, V. M., Alves, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218960
Алексеева, Л. И., Terpigorev, S. A., Zonova, E. V., Kudelya, L. M., Бабадаева, Н. М., Валентиновна, Т. А., Александрович, К. А., Orlov, D. N., Raskina, T., Аношенкова, О. Н., et al. (2020) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2020-3-113-119
Idiopatinės plaučių fibrozės diagnostikos ir gydymo rekomendacijos 2017
Malakauskas, K., Biekšienė, K., Dobrovolskienė, L., Miliauskas, S., Šarauskas, V., Zaveckienė, J., & Žemaitis, M. (2017) · Pulmonology and allergology · doi:10.37499/pia.207
Nintedanibo veiksmingumas ir saugumas, gydant idiopatinę plaučių fibrozę
Kondratavičienė, L. (2018) · Pulmonology and allergology · doi:10.37499/pia.202
Goodwin, A. T., & Saini, G. (2020) · Breathe · doi:10.1183/20734735.0066-2020
“Furthermore, pulmonary rehabilitation is beneficial even in advanced IPF [14] and, therefore, should be considered at every stage of the disease.”
BackgroundInfluentialFibrobronchoskopijos galimybės diagnozuojant plaučių ligas
Ankudavučius, V., & Miliauskas, S. (2018) · Pulmonology and allergology · doi:10.37499/pia.191
Pirfenidono klinikinio veiksmingumo metaanalizė, gydant idiopatinę plaučių fibrozę
Kalinauskaitė-Žukauskė, V. (2017) · Pulmonology and allergology · doi:10.37499/pia.218
Šiuolaikinės idiopatinės plaučių fibrozės gydymo galimybės
Blažytė, L., & Malakauskas, K. (2015) · Pulmonology and allergology · doi:10.37499/pia.288
Stereoselective Synthesis of (Z)-3-Arylidene-2-oxindoles via a Palladium-Catalyzed Tandem Reaction
Seo, J. H., Park, S., & Shin, K. J. (2020) · Heterocycles · doi:10.3987/com-20-14340
Infecciones y esclerosis sistémica: un desafío emergente
Correa, J. E. B., la Hoz, A. D., López, M. J., Garzón, J., Allanore, Y., & Quintana‐López, G. (2020) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2019.12.007 · Cited by 3
Frantsiyants, E. M., Bandovkina, V. A., Kaplieva, I. V., Trepitaki, L. K., Cheryarina, N. D., & Neskubina, I. V. (2020) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2020-19-5-68-75
Valtchinov, V. I., Seo, J. B., Hida, T., & Hatabu, H. (2020) · Medical radiology · doi:10.1007/978-3-030-43539-4_15
The loss of IL-31 signaling attenuates bleomycin-induced pulmonary fibrosisPreprint
Yombo, D. J. K., Odayar, V., Gupta, N., Jegga, A. G., & Madala, S. K. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.18.423450
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.